1609467-75-5

Upstream product

• 109-77-3 malononitrile 
• 1711-02-0 4-iodobenzoic acid chloride 
• 619-58-9 4-iodobenzoic acid 

Downstream Products

• 1609467-76-6 2-((4-iodophenyl)(methoxy)methylene)malononitrile 
• 1609467-77-7 benzyl 3-[5-amino-4-cyano-3-(4-iodophenyl)-1H-pyrazol-1-yl]piperidine-1-carboxylate 
• 1609467-78-8 benzyl 3-{5-amino-4-cyano-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-pyrazol-1-yl}piperidine-1-carboxylate 
• 1609467-82-4 benzyl 3-(5-amino-3-(4-benzylphenyl)-4-cyano-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1609467-83-5 5-amino-3-(4-benzylphenyl)-1-(piperidin-3-yl)-1H-pyrazole-4-carboxamide 
• 1609466-35-4 5-amino-3-(4-benzylphenyl)-1-(1-cyanopiperidin-3-yl)-1H-pyrazole-4-carboxamide 
• 1609467-84-6 3-[5-acetylamino-4-cyano-3-(4-iodophenyl)-pyrazol-1-yl]piperidine-1-carboxylic acid benzyl ester 
• 1609467-85-7 benzyl 3-{5-acetamido-3-[4-(4-chlorobenzyl)phenyl]-4-cyano-1H-pyrazol-1-yl}piperidine-1-carboxylate 
• 1609468-21-4 benzyl 3-(5-acetamido-3-(4-((4-chlorophenyl)thio)phenyl)-4-cyano-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1609468-22-5 5-amino-3-(4-((4-chlorophenyl)thio)phenyl)-1-(piperidin-3-yl)-1H-pyrazole-4-carbonitrile 

Relevant academic research and scientific papers

Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines

Abnormal activation of B-cell receptor (BCR) signaling plays a key role in the development of lymphoid malignancies, and could be reverted by the simultaneous inhibition of Lyn, Fyn and Blk, three members of the Src family kinase (SFK). Fyn and Blk are al

BRUTON'S TYROSINE KINASE INHIBITORS

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)